Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SKLB 1028

Next Previous
X
Search
Drug Profile

SKLB 1028

Alternative Names: SKLB-1028

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Ouyi Pharmaceutical
  • Class Antineoplastics; Diamines; Piperazines; Purines; Pyridines; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • No development reported Cancer

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Cancer(In volunteers, In adults) in China (PO)
  • 31 Dec 2021 CSPC ZhongQi Pharmaceutical obtains clinical trial approval for SKLB 1028 combined therapy with azacitidine for Acute myeloid leukaemia with FLT3 mutation in China before December 2021
  • 31 Dec 2021 CSPC ZhongQi Pharmaceutical obtains clinical trial approval for SKLB 1028 combined therapy with standard treatment “7+3” for Acute myeloid leukaemia with FLT3 mutation in China before December 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top